Stock Events

Stock Events

Decoy Therapeutics 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q3 2025
Next
-346.87
-232.43
-117.99
-3.56
Expected EPS
-3.5555910720000004
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-10.59MNet Income

Analyst Ratings

$1.90Average Price Target
The highest estimate is 1.90.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FP11.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative therapies for rare genetic diseases, overlapping with Salarius' focus on rare cancers.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a cutting-edge technology that could address cancer in ways competitive to Salarius' approach.
Novartis
NVS
Mkt Cap237.61B
Novartis offers a broad portfolio of oncology drugs, directly competing with Salarius Pharmaceuticals in the cancer treatment market.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a strong presence in oncology and cell therapy, areas that Salarius is also targeting.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has a diverse oncology portfolio, including treatments for rare cancers, making it a direct competitor.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a large and expanding oncology division, competing across a range of cancer treatments, including those for rare cancers.
Merck
MRK
Mkt Cap214.76B
Merck is known for its cancer treatments, including immunotherapies that compete with Salarius' therapeutic approaches.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, with its focus on innovative biologics for cancer treatment, competes in the same biopharmaceutical space as Salarius.

About

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Show more...
CEO
Mr. Mark J. Rosenblum CPA
Employees
2
Country
US
ISIN
US79400X6022
WKN
000A424DB

Listings

F
DE
FP11.F
XNAS
US
DCOY
BOATS
BOATS
DCOY.BOATS

0 Comments

Share your thoughts

FAQ

What is Decoy Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Decoy Therapeutics stocks are traded under the ticker FP11.F.
When is the next Decoy Therapeutics earnings date?▼
Decoy Therapeutics is going to release the next earnings report on May 14, 2026.
What were Decoy Therapeutics earnings last quarter?▼
FP11.F earnings for the last quarter are -18.69 EUR per share, whereas the estimation was -346.87 EUR resulting in a +94.61% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Decoy Therapeutics revenue for the last year?▼
Decoy Therapeutics revenue for the last year amounts to 0 EUR.
What is Decoy Therapeutics net income for the last year?▼
FP11.F net income for the last year is -10.59M EUR.
How many employees does Decoy Therapeutics have?▼
As of April 02, 2026, the company has 2 employees.
In which sector is Decoy Therapeutics located?▼
Decoy Therapeutics operates in the Health Care sector.
When did Decoy Therapeutics complete a stock split?▼
The last stock split for Decoy Therapeutics was on March 09, 2026 with a ratio of 1:12.
Where is Decoy Therapeutics headquartered?▼
Decoy Therapeutics is headquartered in Houston, US.